|   | Delaware                                                             | 33-1131287                            |   |
|--------|----------------------------------------------------------------------|---------------------------------------|--------|
|   | ______________________(State or other jurisdiction of                | ____________(I.R.S. employer          |   |
|   | incorporation or organization)                                  | identification number)                |   |
|   |                                                                 |                                  |   |
|   | 933 Mamaroneck Avenue, Suite 103                                     |                                  |   |
|   | Mamaroneck, NY                                                       | 10543                                 |   |
|   | ______________________(Address of principal executive offices)  | ____________(Zip                Code) |   |

----

**NAREK      PHARMACEUTICALS, INC.**

**-      INDEX -**

**PART      I - FINANCIAL INFORMATION**

|                                                                                            | Page                                                                                                                           |
|-------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Item                1. Financial Statements:                                                    |                                                                                                                           |
|                                                                                            |                                                                                                                           |
|                                                                                            | Balance                Sheet as of September 30, 2007 (Unaudited)                                                              | F-1 |
|                                                                                            |                                                                                                                           |
|                                                                                            | Statements                of Operations (Unaudited) for the Three Months Ended September 30,                2007               | F-2 |
|                                                                                            | and                2006, for the Six Months Ended September 30, 2007, for the Period                January                24, |   |
|                                                                                            | 2006                (Inception) Through September 30, 2006 and for the Period January                24,                2006   |   |
|                                                                                            | (Inception)                Through September 30, 2007                                                                          |   |
|                                                                                            |                                                                                                                           |
|                                                                                            | Statement                of Stockholder’s Deficiency for the Period January 24, 2006 (Inception)                         | F-3 |
|                                                                                            | Through                September 30, 2007 (Unaudited)                                                                          |   |
|                                                                                            |                                                                                                                           |
|                                                                                            | Statements                of Cash Flows for the Six Months Ended September 30, 2007 (Unaudited),                               | F-4 |
|                                                                                            | for                the Period January 24, 2006 (Inception) Through September 30,                2006                           |   |
|                                                                                            | (Unaudited)                and for the Period January 24, 2006 (Inception) Through                                             |   |
|                                                                                            | September                30, 2007 (Unaudited)                                                                                  |   |
|                                                                                            |                                                                                                                           |
|                                                                                            | Notes                to Unaudited Financial Statements                                                                         | F-5 |
|                                                                                            |                                                                                                                           |
| Item                2. Management's Discussion and Analysis or Plan of                Operation | 1                                                                                                                              |
|                                                                                            |                                                                                                                           |
| Item                3. Controls and Procedures                                                  | 1                                                                                                                              |
|                                                                                            |                                                                                                                           |
| **PART                II - OTHER INFORMATION**:                                                 |                                                                                                                           |
|                                                                                            |                                                                                                                           |
| Item                1. Legal Proceedings                                                        | 1                                                                                                                              |
|                                                                                            |                                                                                                                           |
| Item                2. Unregistered Sales of Equity Securities and Use of Proceeds              | 1                                                                                                                              |
|                                                                                            |                                                                                                                           |
| Item                3. Defaults Upon Senior Securities                                          | 1                                                                                                                              |
|                                                                                            |                                                                                                                           |
| Item                4. Submission of Matters to a Vote of Security Holders                      | 1                                                                                                                              |
|                                                                                            |                                                                                                                           |
| Item                5. Other Information                                                        | 2                                                                                                                              |
|                                                                                            |                                                                                                                           |
| Item                6. Exhibits                                                                 | 2                                                                                                                              |
|                                                                                            |                                                                                                                           |
| Signatures                                                                                      | 3                                                                                                                              |

----

**PART      I - FINANCIAL INFORMATION**

**Item      1. Financial Statements.**

| NAREK                PHARMACEUTICALS, INC.                                |
|---------------------------------------------------------------------------|
| (A                Development Stage Company)                              |
| BALANCE                SHEET                                              |
|                                                                      |   |    |   |
| Assets                                                                    |
|                                                                      |   |  September                30, 2007 |   |
|                                                                      |   |  (UNAUDITED) |   |
|                                                                      |   |    |   |
| Current                Assets                                             |   |    |   |
| Cash                                                                      |   | $ | 1,570 |   |
|                                                                      |   |   |   |   |
|  Total                Assets                                         |   | $ | 1,570 |   |
|                                                                      |   |   |   |   |
|                                                                      |   |   |   |   |
| Liabilities                and Stockholder's (Deficiency)                 |
|                                                                      |   |   |   |   |
| Current                Liabilities                                        |   |   |   |   |
| Accrued                expenses                                           |   | $ | 1,500 |   |
|                                                                      |   |   |   |   |
| Other                Liabilities                                          |   |   |   |   |
| Notes                payable - stockholder                                |   |   | 59,600 |   |
| Accrued                interest payable                                   |   |   | 2,247 |   |
|  Total                Other Liabilities                              |   |   | 61,847 |   |
|                                                                      |   |   |   |   |
|  Total                Liabilities                                    |   |   | 63,347 |   |
|                                                                      |   |   |   |   |
| Stockholder's                Deficiency                                   |   |   |   |   |
| Preferred                stock, $.0001 par value, 10,000,000              |   |   |   |   |
|  shares                authorized; none outstanding                  |   |   | - |   |
| Common                stock, $.0001 par value; 125,000,000 shares         |   |   |   |   |
|  authorized;                14,000,000 shares issued and outstanding |   |   | 1,400 |   |
| Deficit                accumulated during the development stage           |   |   | (63,177 | ) |
|                                                                      |   |   |   |   |
|  Total                Stockholder's (Deficiency)                     |   |   | (61,777 | ) |
|                                                                      |   |   |   |   |
|  Total                Liabilities and Stockholder's (Deficiency)     |   | $ | 1,570 |   |

----

| NAREK                PHARMACEUTICALS, INC.                |
|-----------------------------------------------------------|
| (A                Development Stage Company)              |
| STATEMENTS                OF OPERATIONS                   |
| (Unaudited)                                               |
|                                                      |   |    |   | FOR                THE PERIOD |   | FOR                THE PERIOD |   |
|                                                      |   |   |   | JANUARY                24, 2006 |   | JANUARY                24, 2006 |   |
|                                                      |   | FOR                THE NINE |   | (INCEPTION) |   | (INCEPTION) |   |
|                                                      |   |  MONTHS                ENDEDSEPTEMBER                30, 2007 |   | THROUGHSEPTEMBER                30, 2006 |   | THROUGHSEPTEMBER                30, 2007 |   |
|                                                      |   |    |   |   |   |   |   |
| Revenue                                                   |   | $ | - |   | $ | - |   | $ | - |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| General                and administrative expenses        |   | $ | 23,295 |   | $ | 28,559 |   | $ | 55,648 |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Loss                before interest expense               |   |   | (23,295 | ) |   | (28,559 | ) |   | (55,648 | ) |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Interest                expense                           |   |   | 1,686 |   |   | 787 |   |   | 2,929 |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Net                loss                                   |   | $ | (24,981 | ) | $ | (29,346 | ) | $ | (58,577 | ) |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Basic                and diluted net loss per share       |   | $ | (0.00 | ) | $ | (0.00 | ) |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Weighted                average common shares outstanding |   |   | 14,000,000 |   |   | 12,848,101 |   |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
|                                                      |   |    | FOR                THE THREE MONTHS ENDED |   |   |   |   |
|                                                      |   |   | SEPTEMBER                30, 2007 |   |   | SEPTEMBER                30, 2006 |   |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Revenue                                                   |   | $ | - |   | $ | - |   |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| General                and administrative expenses        |   |   | 7,208 |   |   | 10,250 |   |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Loss                before interest expense               |   |   | (7,208 | ) |   | (10,250 | ) |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Interest                expense                           |   |   | 682 |   |   | 345 |   |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Net                loss                                   |   | $ | (7,890 | ) | $ | (10,595 | ) |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Basic                and diluted net loss per share       |   | $ | (0.00 | ) | $ | (0.00 | ) |   |   |   |
|                                                      |   |   |   |   |   |   |   |   |   |   |
| Weighted                average common shares outstanding |   |   | 14,000,000 |   |   | 14,000,000 |   |   |   |   |

----

| NAREK                PHARMACEUTICALS, INC.                                            |
|---------------------------------------------------------------------------------------|
| (A                Development Stage Company)                                          |
| STATEMENT                OF STOCKHOLDER'S DEFICIENCY                                  |
| FOR                THE PERIOD JANUARY 24, 2006 (Inception) THROUGH SEPTEMBER 30, 2007 |
|                                                                                  |   |   |   |   |   |   |   |   |   |
|                                                                                  |   |   |   |   |   | Deficit |   |   |   |
|                                                                                  |   |   |   |   |   | Accumulated |   |   |   |
|                                                                                  |   |   |   |   |   | During                the |   | Total |   |
|                                                                                  |   | Common                Stock |   | Development |   | Stockholder's |   |
|                                                                                  |   | Shares |   | Amount |   | Stage |   | (Deficiency) |   |
| Balance,                January 24, 2006 (inception)                                  |   |   | - |   | $ | - |   | $ | - |   | $ | - |   |
|                                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance                of 14,000,000 shares of common stock                          |   |   | 14,000,000 |   |   | 1,400 |   |   | - |   |   | 1,400 |   |
|                                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net                loss - January 24, 2006 through December 31, 2006                  |   |   | - |   |   | - |   |   | (46,095 | ) |   | (46,095 | ) |
|                                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance,                December 31, 2006                                             |   |   | 14,000,000 |   |   | 1,400 |   |   | (46,095 | ) |   | (44,695 | ) |
|                                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net                loss - January 1, 2007 through September 30, 2007 (Unaudited)      |   |   | - |   |   | - |   |   | (24,981 | ) |   | (24,981 | ) |
|                                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Balance,                September 30, 2007 (Unaudited)                                |   |   | 14,000,000 |   | $ | 1,400 |   | $ | (71,076 | ) | $ | (69,676 | ) |

----

| NAREK                PHARMACEUTICALS, INC.               |
|----------------------------------------------------------|
| (A                Development Stage Company)             |
| STATEMENTS                OF CASH FLOWS                  |
|                                                     |   |   |   |   |   |   |   |
|                                                     |   |   |   | FOR                THE PERIOD |   | FOR                THE PERIOD |   |
|                                                     |   |   |   | JANUARY                24, 2006 |   | JANUARY                24, 2006 |   |
|                                                     |   |   |   | (INCEPTION) |   | (INCEPTION) |   |
|                                                     |   | NINE                  MONTHS ENDED SEPTEMBER 30, 2007 |   | THROUGH                SEPTEMBER 30, 2006 |   | THROUGHSEPTEMBER                30, 2007 |   |
|                                                     |   | (UNAUDITED) |   | (UNAUDITED) |   | (UNAUDITED) |   |
|                                                     |   |   |   |   |   |   |   |
| Cash                flows from operating activities:     |   |   |   |   |   |   |   |
|                                                     |   |   |   |   |   |   |   |
| Net                loss                                  |   | $ | (24,981 | ) | $ | (29,346 | ) | $ | (71,076 | ) |
| Changes                in assets and liabilities         |   |   |   |   |   |   |   |   |   |   |
| Increase                (Decrease) in accrued expenses   |   |   | (2,000 | ) |   | 2,943 |   |   | 1,500 |   |
| Increase                in accrued interest payable      |   |   | 1,686 |   |   | - |   |   | 2,929 |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
| Net                cash used in operating activities     |   |   | (25,295 | ) |   | (26,403 | ) |   | (66,647 | ) |
|                                                     |   |   |   |   |   |   |   |   |   |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
| Cash                flows from financing activities:     |   |   |   |   |   |   |   |   |   |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
| Proceeds                from notes payable - stockholder |   |   | 28,500 |   |   | 41,100 |   |   | 69,600 |   |
| Proceeds                from issuance of common stock    |   |   | - |   |   | 1,400 |   |   | 1,400 |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
| Net                cash provided by financing activities |   |   | 28,500 |   |   | 42,500 |   |   | 71,000 |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
| Increase                in cash                          |   |   | 3,205 |   |   | 16,097 |   |   | 4,353 |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
| Cash,                beginning of period                 |   |   | 1,147 |   |   | - |   |   | - |   |
|                                                     |   |   |   |   |   |   |   |   |   |   |
| Cash,                end of period                       |   | $ | 4,352 |   | $ | 16,097 |   | $ | 4,353 |   |

----

**NAREK      PHARMACEUTICALS,INC**
**.**

**(A      Development Stage Company)**

**NOTES      TO FINANCIAL STATEMENTS**

**September      30, 2007**

**(UNAUDITED)**

**NOTE      1 - OPERATIONS **

**Narek      Pharmaceuticals, Inc. (the “Company”) was incorporated in the state of Delaware      on January 24, 2006. **

**The      Company has been in the development stage since its inception, developing its      business plans and seeking potential merger targets. There have been no      operations or revenue since inception.**

**NOTE      2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis      of Presentation**

**The      accompanying financial statements have been prepared assuming the Company will      continue as a going concern. The Company has a deficit accumulated during the      development stage and deficiencies in stockholder’s equity and working capital      at September 30, 2007. Management plans to issue more shares of common stock      in      order to raise money and to continue to borrow funds from the existing      stockholder until a merger can be consummated. The accompanying financial      statements do not include any adjustments that might be required should the      company be unable to recover the value of its assets or satisfy its      liabilities.**

**Use      of Estimates**

**The      preparation of financial statements in conformity with accounting principles      generally accepted in the United States requires management to make estimates      and assumptions that affect the reported amounts of assets and liabilities      and      the disclosure of contingent assets and liabilities at the date of the financial      statements and revenues and expenses during the reporting period. Actual results      could differ from those estimates.**

**Cash      & Cash Equivalents**

**For      purposes of the statement of cash flows, the Company considers highly liquid      financial instruments purchased with a maturity of three months or less to      be      cash equivalents. At September 30, 2007, the Company has no cash      equivalents.**

**Income      Taxes**

**The      Company follows the provisions of Statement of Financial Accounting Standards      Board No. 109, “Accounting for Income Taxes,” which requires the use of the      liability method of accounting for income taxes by applying enacted statutory      rates in effect at the balance sheet date to the differences between the tax      basis of assets and liabilities and their reported amounts on the financial      statements. A valuation allowance is provided when it is more likely than not      that a deferred tax asset will not be realized. The Company’s gross deferred tax      asset of approximately $15,000 at September 30, 2007 has been fully offset      by a      valuation allowance. **

----

**NAREK      PHARMACEUTICALS,INC**
**.**

**(A      Development Stage Company)**

**NOTES      TO FINANCIAL STATEMENTS**

**SEPTEMBER      30, 2007**

**(UNAUDITED)**

**NOTE      2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued**

**Loss      per Common Share**

**Basic      net loss per share was computed by dividing net loss for the year by the      weighted average number of shares outstanding during the year. Diluted loss      per      share includes potentially dilutive securities such as outstanding options      and      warrants, using various methods such as the treasury stock method in the      determination of dilutive shares outstanding during each reporting period The      Company does not have any potentially dilutive instruments.**

**Financial      Instruments**

**The      carrying amounts of financial instruments, including current assets and      liabilities, approximate fair value because of their relatively short maturity.      **

**NOTE      3 - NOTES PAYABLE TO STOCKHOLDER**

**On      February 6, 2006 and July 13, 2006, the Company issued 4.00% promissory notes      payable for $31,100 and $10,000, respectively, to Dr. Anna Kazanchyan, the      Company’s sole officer, director and stockholder. The Notes and all accrued      interest mature upon completion of merger, and if no merger is consummated,      then      the Notes will reach maturity on December 31, 2010.**

**On      March 16, 2007, the Company issued the same person a 8.25% promissory note      payable for $3,500. This note and all accrued interest mature at the earlier      of      completion of merger at maturity on or before March 16,      2009.**

**On      May 30, 2007, the Company issued the same person a 8.25% promissory note payable      for $15,000. This note and all accrued interest mature at the earlier of      completion of merger or May 30, 2009.**

**On      August 20, 2007, an additional amount of $10,000 was loaned from the sole      officer, director and stockholder of the Company. This amount plus accrued      interest is payable upon completion of merger.**

----

**NAREK      PHARMACEUTICALS,INC**
**.**

**(A      Development Stage Company)**

**NOTES      TO FINANCIAL STATEMENTS**

**SEPTEMBER      30, 2007**

**(UNAUDITED)**

**NOTE      4 - CAPITAL STOCK**

**The      total number of shares of capital stock which the Company is authorized to      issue      is 135,000,000, of which 125,000,000 shares are designated as common stock      at      $.0001 par value (the “Common Stock”) and 10,000,000 shares are designated as      preferred stock at $.0001 par value (the “Preferred Stock”). The Preferred Stock      of the Company shall have such voting powers, full or limited, or no voting      powers, and such designations, preferences, limitations or restrictions as      the      Board of Directors of the Company may determine, from time to      time.**

**Holders      of shares of Common Stock shall be entitled to cast one vote for each share      held      at all stockholder meetings for all purposes, including the election of      directors. The Common Stock does not have cumulative voting      rights.**

**On      February 6, 2006, the Company issued 14,000,000 shares of Common Stock at a      purchase price of $.0001 per share.**

**NOTE      5 - **
**NEW      ACCOUNTING PRONOUNCEMENTS**

**In      September 2006, the Financial Accounting Standards Board issued Statement      of Financial Accounting Standards No. 157, “Fair Value Measurements,” (“FAS      157”). FAS 157 defines fair value, establishes a framework for measuring fair      value and expands disclosures about fair value measurements. The adoption of      FAS      157 is effective January 1, 2008. The Company has not yet determined what      the effect will be, if any, on its financial statements.**

**In      February 2007, the Financial Accounting Standards Board issued Statement of      Financial Accounting Standards No. 159 (“FAS 159”), The Fair Value Option for      Financial Assets and Financial Liabilities, which permits entities to choose      to      measure many financial instruments and certain other items at fair value which      are not currently required to be measured at fair value. FAS 159 is effective      for financial statements issued for fiscal years beginning after November 15,      2007, and interim periods within those fiscal years. The Company does not expect      the adoption of FAS 159 to have an effect on its financial      statements.**

**Management      does not believe that any other recently issued, but not yet effective      accounting pronouncements, if adopted, would have a material effect on the      accompanying consolidated financial statements.**

----

**NAREK      PHARMACEUTICALS,INC**
**.**

**(A      Development Stage Company)**

**NOTES      TO FINANCIAL STATEMENTS**

**SEPTEMBER      30, 2007**

**(UNAUDITED)**

**NOTE      6 - INTERIM FINANCIAL STATEMENTS**

**The      accompanying Interim Financial Statements of the Company as of September 30,      2007, and for the period from January 24, 2006 (inception) through September      30,      2007 have been prepared in accordance with accounting principles generally      accepted for interim financial statement presentation and in accordance with      the      instructions to Regulations S-B. Accordingly, they do not include all of the      information and footnotes required by accounting principles generally accepted      in the United States for complete financial statement presentation. In the      opinion of management, all adjustments for a fair statement of the results      and      operations and financial position for the interim periods presented have been      included.**

**All      such adjustments are of a normal recurring nature. The financial information      should be read in conjunction with the Financial Statements and notes thereto      included in the Company’s Form 10-KSB for the period January 24, 2006      (inception) through December 31, 2006. There have been no changes in significant      accounting policies since December 31, 2006.**

----

**Item      2. Management’s Discussion and Analysis or Plan of Operation.**

**Item      3. Controls and Procedures.**

**PART      II — OTHER INFORMATION**

**Item      1. Legal Proceedings.**

**Item      2. Unregistered Sales of Equity Securities and Use of Proceeds.**

**Item      3. Defaults Upon Senior Securities.**

**Item      4. Submission of Matters to a Vote of Security Holders.**

----

**Item      5. Other Information.**

**Item      6. Exhibits.**

|   | Exhibit | Description |
|--------|---------|-------------|
|   |   |   |
|--------|--------|--------|
|  | *3.1 | Certificate                of Incorporation, as filed with the Delaware Secretary of State on                January                24, 2006. |
|--|------|-----------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |   |
|--------|--------|--------|
|   | *3.2 | By-laws. |
|--------|------|----------|
|   |   |   |
|--------|--------|--------|
|   | 31.1 | Certification of the Company’s Principal              Executive Officer and Principal Financial Officer pursuant to Section              302              of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s              Quarterly Report on Form 10-QSB for the quarter ended September 30,              2007. |
|--------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |   |
|--------|--------|--------|
|   | 32.1 | Certification of the Company’s Principal              Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.              Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley              Act              of 2002. |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| * | Filed                as an exhibit to the Company's registration statement on Form 10-SB,                as                filed with the Securities and Exchange Commission on May 26, 2006,                and                incorporated herein by this                reference. |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**SIGNATURES**

|                                      |                                     |                               |
|-------------------------------------------|------------------------------------------|------------------------------------|
|                                      | NAREK              PHARMACEUTICALS, INC. |
|                                 |                                |                          |
| Date: November              19, 2007 | By:                            | /s/ Jason              Rogers |
|                                      | Name:              Jason Rogers          |
|                                      | Title:              President       |

----